News
Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...
Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market ...
Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.
Health news highlights the booming demand for obesity drugs in India with companies like Eli Lilly and Novo Nordisk vying for ...
Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst ...
The demand for weight-loss medications is rapidly increasing in India, with competitors Eli Lilly and Novo Nordisk vying for ...
Pharmarack Technologies' revenue model is subscription-based, where customers can either opt for a flat fee that can be paid on a monthly basis, or they can opt for the pay-per-use model.
Pharmarack is part of Inc42’s 42 Fellowship – a year-long fellowship programme for India’s top growing and upcoming startups with the aim to build a close-knit community who can help each ...
The Karnataka Chemists and Druggists Association (KCDA) is concerned over Pharmarack’s recent move in which it has communicated to all the stockists in the state insisting them to order directly from ...
SINGAPORE--(BUSINESS WIRE)--Informatica (NYSE: INFA), an enterprise cloud data management leader, today announced that Pharmarack, India’s largest commerce-to-insights technology company, has ...
Hosted on MSN1mon
Eli Lilly is said to have posted 60% rise in obesity drug sales in India last month - MSNCiting data from India-based market analysis firm Pharmarack Technologies, the publication said Lilly (NYSE:LLY) recorded ₹126M ($1.5M) worth of Mounjaro sales last month.
Pune-based Pharmarack has raised $3 Mn in a Series A funding round from IvyCap Ventures. As part of the deal, the IvyCap Ventures’ founder and managing partner Vikram Singh will join the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results